Q: Hi,
HEPION Parma (HEPA-US: not in your database) had a 1/20 reverse stock split this week. Taking this into account, the stock is still nearly down 50% in 2 days. Liver/ NASH disease is a good research target. Any news I did not see?
Have a great week-end. Thanks
HEPION Parma (HEPA-US: not in your database) had a 1/20 reverse stock split this week. Taking this into account, the stock is still nearly down 50% in 2 days. Liver/ NASH disease is a good research target. Any news I did not see?
Have a great week-end. Thanks
